Victory Capital Management
KALV

Victory Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Victory Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-95,836
Closed -$1.16M – 2525
2020
Q2 		$1.16M Sell
95,836
-436,440
-82% -$4.64M ﹤0.01% 1653
2020
Q1 		$4.07M Buy
532,276
+257,185
+93% +$3.47M ﹤0.01% 1331
2019
Q4 		$4.9M Buy
275,091
+273,352
+15,719% +$3.57M 0.01% 1194
2019
Q3 		$20K Buy
+1,739
New +$28.1K ﹤0.01% 3042

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Victory Capital Management's KALV Position: Q3 2020 in Review

Victory Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2020, closing a stake of 95,836 shares — an estimated $1.16M sold.

Victory Capital Management first reported a position in KALV in Q3 2019 and held it in 4 quarters. The position peaked at $4.9M in Q4 2019. 63 funds tracked by Wall St. Rank hold KALV as of Q3 2020.

  • Victory Capital Management reported no remaining KalVista Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Victory Capital Management sold 95,836 KalVista Pharmaceuticals shares in Q3 2020, an estimated $1.16M.
  • Victory Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Victory Capital Management's KalVista Pharmaceuticals position peaked at $4.9M in Q4 2019.
  • 63 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2020.

Based on Victory Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.